Rezolute (RZLT) said the US Food and Drug Administration granted breakthrough therapy designation for its investigational treatment for ersodetug, a treatment for hypoglycemia caused by tumor hyperinsulinism.
The designation was awarded based on clinical trial data across an overall development program that showed the treatment works in a way that directly targets the underlying cause of the tumor hyperinsulinism, the company said Monday in a statement.
Rezolute plans to start a registrational study of the drug in patients with tumor hyperinsulinism in the middle of this year with topline results expected in H2 2026.
The company is also evaluating ersodetug for the treatment of hypoglycemia caused by congenital hyperinsulinism in a Phase 3 trial.
Price: 4.01, Change: +0.01, Percent Change: +0.25
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。